Patent Application Cites Cleanascite™ In Methods to Diagnose Insulin Resistance

MONMOUTH JUNCTION, N.J. - April 6, 2019 - PRLog -- Biotech Support Group reports on a recent patent application describing the simplicity and efficiency of their lipid clearance sample preparation technology for reducing analytical variables in liquid chromatography coupled to mass spectrophotometric (LC-MS) analysis of insulin and C-peptide. The citation is:

Shiffman, Dov, et al. "Methods for quantitation of insulin and c-peptide (https://patents.google.com/patent/US20190079070A1/en)." U.S. Patent Application No. 15/942,188.

The inventors describe methods for diagnosing or prognosing insulin resistance in diabetic and pre-diabetic patients, the method comprising determining the amount of insulin and C-peptide in a sample. Mass spectrometric methods are described for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques. The application states "In some embodiments, serum is delipidated prior to quantitation by mass spectrometry. … In some embodiments, the delipidation reagent is CLEANASCITE".

"This patent application justifies the value of Cleanascite™ as a serum delipidation reagent so that better quantitative analysis of targeted protein analytes can be monitored by LC-MS." states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
https://www.biotechsupportgroup.com/Articles.asp?ID=456

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.

Contact:
Matthew Kuruc
732-274-2866,
mkuruc@biotechsupportgroup.com